Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib
Panagiotis Efentakis(National and Kapodistrian University of Athens), Evangelos Terpos(National and Kapodistrian University of Athens)
Cited by 24
Related Papers
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493
Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
|Journal of Clinical Oncology|2010|409
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266